

**7th Annual Philadelphia-Japan Health Sciences Dialogue***In conjunction with the Licensing Executives Society (LES) and
Association of University Technology Managers (AUTM) Joint Spring Meeting***Therapies for Cancer**

Tuesday, May 9, 2006 *The Union League of Philadelphia*
 8:00 a.m. *Registration and continental breakfast*
 8:15 a.m. – 5:00 p.m. *Program (Lunch included)*
 5:00 p.m. – 6:30 p.m. *Cocktail Networking Reception*

Online Registration at www.jasgp.org/hsd

Registration: \$400 JASGP, NY Pharma Forum, JETRO NY Healthcare Study Group, PA BIO, LES, AUTM Members, Academia & Government; \$500 Non-members

OVERVIEW

Cancer remains one of the most vexing health care problems facing the world, both in terms of therapy and cost. This is not for want of effort by institutions and businesses seeking solutions. There has been a proliferation of entities addressing the problem and a multitude of proposed solutions. Both Japan and the United States have been leaders in discovery and adoption of new therapeutic approaches. Progress had been slow, but there has been progress in fighting many forms of cancer. The amount of money being spent in cancer therapeutics research continues to grow. The 7th Annual Philadelphia-Japan Health Sciences Dialogue, featuring distinguished leaders in the field, is designed to take stock of what is happening in Japan and the United States in the fight against cancer, and to discern future trends in this important effort.

- 8:15-8:25 AM** **Welcome**
 Hiroshi Sato, *Deputy Consul General and Deputy Chief of Mission, Consulate General of Japan in New York*
- 8:30-8:50** **Opening Remarks: Transformational Changes in Cancer Research and Treatment**
 Robert C. Young, M.D. *President, Fox Chase Cancer Center*
- 8:50-10:00 AM** **Distinctions and Similarities: Three Perspectives**
 Richard G. Pestell, M.D., Ph.D. *Director, Kimmel Cancer Center, Thomas Jefferson University Hospital*
 Yasuhiro Fujiwara, M.D., *Director, Outpatient Treatment Center, Japan National Cancer Center*
 Frank Pasqualone, *Senior Vice President, Oncology, Bristol-Myers Squibb Co.*
- 10:15-11:30 AM** **Evolving Trends in Cancer Therapy**
 Jeffrey M. Bockman, Ph.D., *Vice President, Defined Health*
 David Jenkins, *Director, Clinical Development, Cervarix TM, GlaxoSmithKline Biologicals*
 William U. Shipley, M.D., *Massachusetts General Hospital Cancer Center*
- 11:30-12:15 PM** **Product Pipeline: Targeted ≠ Narrow**
 Karen Bernstein, *Chairman & Editor-in-Chief, BioCentury*
- 12:15-1:45 PM** **Luncheon Address: Diagnostics & Biomarkers**
 Sean McDonald, *President and CEO, Precision Therapeutics, Inc.*
Moderator: Pradip K. Banerjee, Ph.D., *President and CEO, Science Center*
- 1:45-2:30 PM** **Unique Quality of Cancer Clinical Trials**
 Philip Sass, Ph.D., *Executive Vice President & Chief Operating Officer, Morphotek Inc.*
 Linda Faux, *Senior Director, Clinical Project Management, AstraZeneca Pharmaceuticals*
- 2:30-3:30 PM** **Licenses and Business Development: Big Pharma**
 Ben Bonifant, *Senior Practice Executive, Business Development Practice, Campbell Alliance*
 Nobuo Hanai, Ph.D., *President and CEO, BioWa*
- 3:45-4:45 PM** **Licenses and Business Development: The Biotechs**
 John Gill, *President & CEO, TetraLogic Pharmaceutical Corporation*
 Ronald A. Pepin, Ph.D., *Senior Vice President, Business Development, Medarex, Inc.*
 Masashi Suganuma, M.D., Ph.D., *Vice President & COO, CanBas Co., Ltd.*
- 4:45-5:00 PM** **Closing Remarks**
 Richard G. Pestell, M.D., Ph.D. *Director, Kimmel Cancer Center, Thomas Jefferson University Hospital*